Literature DB >> 31270696

Predictors and the optimal duration of sustained remission in rheumatoid arthritis.

Sibel Yilmaz-Oner1, Ummugulsum Gazel2, Meryem Can2, Pamir Atagunduz2, Haner Direskeneli2, Nevsun Inanc2.   

Abstract

OBJECTIVE: To determine predictors and optimal duration of sustained remission (SR) in patients with rheumatoid arthritis (RA).
METHODS: A total of 428 consecutive patients with RA visiting our clinic routinely between 2012 and 2013 were evaluated. Seventy seven of these patients in DAS28 remission were enrolled and followed up for 62.2 ± 9.9 months. Patients in remission ≥ 6 months (SR) and shorter (non: N-SR) were compared in terms of demographic-clinical data and the psychosocial factors. At enrollment, 1st and 5th years, patients in DAS28, SDAI, and Boolean remission were determined.
RESULTS: Sixty three patients were in SR and 14 in N-SR. Lower baseline DAS28 and HAQ scores, anti-CCP were positive predictors of SR. Although the presence of anxiety, depression, fibromyalgia, and fatigue were lower in the SR group, there was no significance. Patients in DAS28 remission (100%) at baseline reduced to 64% at 1st and 42.6% at 5th years. Patients satisfying SDAI and Boolean remission at these three visits were 49%, 44%, and 32.4% vs 41%, 28%, and 20.6%, respectively. If the duration of remission is defined as 6 months, the remission rates of SDAI at inclusion and fifth years' visits were similar but Boolean remission rates differed significantly and if it is accepted as ≥ 12 months, both the SDAI and Boolean remission rates were not different.
CONCLUSION: Low DAS28 and HAQ scores at baseline, anti-CCP were positive predictors of SR. Instead of 6 months, remission duration for ≥ 12 months would probably help us to predict SR independently from the chosen criteria; Boolean or SDAI.

Entities:  

Keywords:  ACR/EULAR definition of remission; Disease activity score; Predictors; Rheumatoid arthritis; SDAI; Sustained remission

Year:  2019        PMID: 31270696     DOI: 10.1007/s10067-019-04654-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  47 in total

Review 1.  The health assessment questionnaire 1992: status and review.

Authors:  D R Ramey; J P Raynauld; J F Fries
Journal:  Arthritis Care Res       Date:  1992-09

2.  Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.

Authors:  S Ajeganova; H W van Steenbergen; J A B van Nies; L E Burgers; T W J Huizinga; A H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2015-05-13       Impact factor: 19.103

3.  Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.

Authors:  Sibel Yilmaz-Oner; Gulsen Ozen; Meryem Can; Pamir Atagunduz; Haner Direskeneli; Nevsun Inanc
Journal:  J Rheumatol       Date:  2015-10-15       Impact factor: 4.666

4.  Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity.

Authors:  Nasim A Khan; Horace J Spencer; Esam Abda; Amita Aggarwal; Rieke Alten; Codrina Ancuta; Daina Andersone; Martin Bergman; Jurgen Craig-Muller; Jacqueline Detert; Lia Georgescu; Laure Gossec; Hisham Hamoud; Johannes W G Jacobs; Ieda Maria Magalhaes Laurindo; Maria Majdan; Antonio Naranjo; Sapan Pandya; Christof Pohl; Georg Schett; Zahraa I Selim; Sergio Toloza; Hisahi Yamanaka; Tuulikki Sokka
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

Review 5.  The consequences of rheumatoid arthritis: quality of life measures in the individual patient.

Authors:  L Pollard; E H Choy; D L Scott
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

6.  American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

7.  Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis.

Authors:  P P Katz; E H Yelin
Journal:  J Rheumatol       Date:  1993-05       Impact factor: 4.666

8.  The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.

Authors:  Nevsun Inanc; Sibel Yilmaz-Oner; Meryem Can; Tuulikki Sokka; Haner Direskeneli
Journal:  J Rheumatol       Date:  2014-08-01       Impact factor: 4.666

Review 9.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

10.  Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.

Authors:  Helga Radner; Farideh Alasti; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2015-08-11       Impact factor: 5.156

View more
  1 in total

1.  Clinical conditions needed to acquire sustained functional remission in rheumatoid arthritis patients.

Authors:  Ryousuke Koizumi; Kensuke Koyama; Masanori Wako; Tetsuro Ohba; Yoshihiro Takayama; Hirotaka Haro
Journal:  Clin Rheumatol       Date:  2020-10-11       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.